viewCallitas Health Inc

Callitas Health awarded US patent for male infertility treatment, extending its ToConceive brand

The patent boosts the health and wellness company’s core intellectual property assets linked to its popular female fertility brand

A couple
ToConceive helps couples struggling to conceive a child

Cincinnati-based Callitas Health Inc (CSE:LILY, OTCQB:MPHMF, OTCMKTS: MPHMF) announced Wednesday that its treatment for male infertility received a patent from the United States Patent and Trademark Office.

The health and wellness company said it was granted US Patent No. 10,004,697 for its In Vivo Sperm Selection for treating male Infertility.

The patent essentially expands the company’s intellectual property portfolio while extending the patent-protected formula and uses of its ToConceive product when treating male infertility (or sub-fertility) caused by reduced functional sperm count in the male partner. 

"Male infertility (or sub-fertility) has not received the attention it should," said Callitas Health CEO James Thompson. "Statistics indicate nearly two-thirds of all infertility challenges are linked back to the man and can be further challenged by a lack of lubrication from the woman," he added.

BIG PICTURE: Callitas Health banks on CannaStrips and OTC products while swinging for the fence with blockbuster drugs

The CEO said the full grant of the patent advanced the company’s mission to help couples trying to conceive, whether they're dealing “with male or female infertility or a combination of the two.” 

"This patent grant strengthens the core intellectual property assets of our ToConceive brand and reinforces Callitas' commitment to female sexual health and wellness, as well as male infertility (subfertility), and aiding couples trying to conceive," said Thompson.

Callitas Health has launched ToConceive in North America for couples struggling to conceive a child. It was developed by well-known gynecologic surgeon and infertility specialist Dr Ronald Thompson (father of CEO James Thompson), based on the science behind the 2010 Nobel Prize in Medicine for in vitro fertilization (IVF) and sperm capacitation.

It's FDA-cleared and clinically proven to increase a woman’s own natural conception lubrication, called transudate.

Callitas Health is developing remedies across five silos: OTC sexual health & wellness, prescriptions for female sexual health, weight management, cannabis delivery technologies and orphan drugs.

Contact Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive

Quick facts: Callitas Health Inc

Price: - CAD

Market: CSE
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Chimeric Therapeutics new very experienced COO has bold vision to move CAR T...

Chimeric Therapeutics (ASX: CHM) newly appointed COO Jennifer Chow joined Steve Darling from Proactive to talk about her vision for the company. Chow talks about her background working in cell therapy and how Chimeric hopes to be a big player in it. Chow also told Proactive about their lead...

3 hours, 45 minutes ago

2 min read